Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease Spectrum
Introduction: Myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG)-related disease was initially described as a subtype of neuromyelitis optica spectrum disorder (NMOSD) with antibodies against MOG. However, it has recently been described as a separate disease entity with clinical and radi...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-02-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2020.00089/full |
id |
doaj-7cec7aed2a734b22827519922c07c857 |
---|---|
record_format |
Article |
spelling |
doaj-7cec7aed2a734b22827519922c07c8572020-11-25T01:13:29ZengFrontiers Media S.A.Frontiers in Neurology1664-22952020-02-011110.3389/fneur.2020.00089493096Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease SpectrumFoziah Alshamrani0Hind Alnajashi1Eslam Shosha2Courtney Casserly3Sarah A. Morrow4Department of Neurology, King Fahad University Hospital, Imam Abdulrahman Bin Faisal University, Dammam, Saudi ArabiaDepartment of Neurology, King Abdulaziz University, Jeddah, Saudi ArabiaDepartment of Clinical Neurological Sciences, University of Western Ontario, London, ON, CanadaDepartment of Clinical Neurological Sciences, University of Western Ontario, London, ON, CanadaDepartment of Clinical Neurological Sciences, University of Western Ontario, London, ON, CanadaIntroduction: Myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG)-related disease was initially described as a subtype of neuromyelitis optica spectrum disorder (NMOSD) with antibodies against MOG. However, it has recently been described as a separate disease entity with clinical and radiological features that overlap those of multiple sclerosis (MS) and NMOSD; the clinical features of this disease phenotype remain undetermined. We herein report the clinical presentation of nine MOG-IgG-positive patients, not all of whom fulfill the NMOSD criteria, in order to highlight the features and challenges of this condition.Method: We retrospectively reviewed the records of the London (Ontario) MS clinic to identify patients diagnosed with positive MOG antibodies based on the 2015 NMOSD consensus criteria.Result: Nine patients were identified, all Caucasian. Seven (78%) were female, and the median age of onset was 41 years (range, 28–69 years); the median Expanded Disability Status Scale score at onset was 3.0 (range, 2.0–4.0). A monophasic course was noted in two (22.2%) patients, while the median number of relapse events was 3 (range 2–5) in 77.8% of the patients. Optic neuritis and transverse myelitis contributed equally as initial manifestations in three individuals (33%), while brainstem relapse was reported in two individuals (22%). The brain magnetic resonance imaging findings were compatible with McDonald's 2010 dissemination in space criteria in three cases (33%). Short myelitis and an (H)-sign were each documented in one patient.Conclusion: The phenotypes of MOG Ab-positive cases exhibited overlapping features with MS and NMOSD. This finding highlights the importance of screening for anti-MOG in individuals with demyelinating symptoms, in consideration of the possibility of false-positive MOG Ab results.https://www.frontiersin.org/article/10.3389/fneur.2020.00089/fullmyelin oligodendrocyte glycoproteinoptic neuritisneuromyelitis optica spectrum disordermultiple sclerosistransverse myelitis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Foziah Alshamrani Hind Alnajashi Eslam Shosha Courtney Casserly Sarah A. Morrow |
spellingShingle |
Foziah Alshamrani Hind Alnajashi Eslam Shosha Courtney Casserly Sarah A. Morrow Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease Spectrum Frontiers in Neurology myelin oligodendrocyte glycoprotein optic neuritis neuromyelitis optica spectrum disorder multiple sclerosis transverse myelitis |
author_facet |
Foziah Alshamrani Hind Alnajashi Eslam Shosha Courtney Casserly Sarah A. Morrow |
author_sort |
Foziah Alshamrani |
title |
Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease Spectrum |
title_short |
Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease Spectrum |
title_full |
Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease Spectrum |
title_fullStr |
Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease Spectrum |
title_full_unstemmed |
Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease Spectrum |
title_sort |
case series: myelin oligodendrocyte glycoprotein-immunoglobulin g-related disease spectrum |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2020-02-01 |
description |
Introduction: Myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG)-related disease was initially described as a subtype of neuromyelitis optica spectrum disorder (NMOSD) with antibodies against MOG. However, it has recently been described as a separate disease entity with clinical and radiological features that overlap those of multiple sclerosis (MS) and NMOSD; the clinical features of this disease phenotype remain undetermined. We herein report the clinical presentation of nine MOG-IgG-positive patients, not all of whom fulfill the NMOSD criteria, in order to highlight the features and challenges of this condition.Method: We retrospectively reviewed the records of the London (Ontario) MS clinic to identify patients diagnosed with positive MOG antibodies based on the 2015 NMOSD consensus criteria.Result: Nine patients were identified, all Caucasian. Seven (78%) were female, and the median age of onset was 41 years (range, 28–69 years); the median Expanded Disability Status Scale score at onset was 3.0 (range, 2.0–4.0). A monophasic course was noted in two (22.2%) patients, while the median number of relapse events was 3 (range 2–5) in 77.8% of the patients. Optic neuritis and transverse myelitis contributed equally as initial manifestations in three individuals (33%), while brainstem relapse was reported in two individuals (22%). The brain magnetic resonance imaging findings were compatible with McDonald's 2010 dissemination in space criteria in three cases (33%). Short myelitis and an (H)-sign were each documented in one patient.Conclusion: The phenotypes of MOG Ab-positive cases exhibited overlapping features with MS and NMOSD. This finding highlights the importance of screening for anti-MOG in individuals with demyelinating symptoms, in consideration of the possibility of false-positive MOG Ab results. |
topic |
myelin oligodendrocyte glycoprotein optic neuritis neuromyelitis optica spectrum disorder multiple sclerosis transverse myelitis |
url |
https://www.frontiersin.org/article/10.3389/fneur.2020.00089/full |
work_keys_str_mv |
AT foziahalshamrani caseseriesmyelinoligodendrocyteglycoproteinimmunoglobulingrelateddiseasespectrum AT hindalnajashi caseseriesmyelinoligodendrocyteglycoproteinimmunoglobulingrelateddiseasespectrum AT eslamshosha caseseriesmyelinoligodendrocyteglycoproteinimmunoglobulingrelateddiseasespectrum AT courtneycasserly caseseriesmyelinoligodendrocyteglycoproteinimmunoglobulingrelateddiseasespectrum AT sarahamorrow caseseriesmyelinoligodendrocyteglycoproteinimmunoglobulingrelateddiseasespectrum |
_version_ |
1725161920178159616 |